However, although lorlatinib is expected to be a new first-line treatment for ALK-p advanced NSCLC, there have been no RCTs comparing its efficacy with that of alectinib, the current first-line treatment for ALK-p advanced NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.